Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29411287 | 1.00 | PDXK (0.31) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16635292 | 0.80 | KDM4E (0.31) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29411237 | 0.79 | — | — | |
| SCHEMBL19794768 | 0.79 | — | — | |
| SCHEMBL23500825 | 0.78 | UHRF1 (0.39) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15526484 | 0.78 | RECQL (0.39) | PDXK | |
| SCHEMBL20972138 | 0.78 | PTGDR2 (0.32) | HSD17B10PTGDR2 | |
| SCHEMBL16122485 | 0.78 | GABRP (0.42) | — | |
| SCHEMBL17781576 | 0.78 | PDXK (0.37) | PDXK | |
| SCHEMBL21713991 | 0.78 | SHBG (0.38) | PDXKKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| CN-109476640-B | Bicyclic proline compounds | 豪夫迈·罗氏有限公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2021011713-A1 | IMIDAZOPYRIMIDINES AS EED INHIBITORS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-01-21 | — | — | WO | disclosed |
| US-10597383-B2 | Bicyclic proline compounds | GENENTECH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| EP-3487853-A1 | BICYCLIC PROLINE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | GENENTECH, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | GENENTECH, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2018015410-A1 | BICYCLIC PROLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| WO-2018015410-A1 | BICYCLIC PROLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
| US-5536745-A | (Hetero)-aryl ketones derivatives with antibacterial properties | SMITHKLINE BEECHAM P.L.C. (GB) | 1996-07-16 | — | — | US | disclosed |
| EP-0652875-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002478-A1 | (HETERO)-ARYL KETONES DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10597383-B2 | Bicyclic proline compounds | TRPA1, TRPV1, TRPV5 | PDXK 818/4885KDM4E 4238/4885ALDH1A1 528/4885 |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | TRPA1, TRPV1, TRPV5 | PDXK 818/4885KDM4E 4238/4885ALDH1A1 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.